Tecentriq and Tecentriq Hybreza bladder cancer MRD access guide: the first ctDNA-guided adjuvant immunotherapy, companion diagnostic, coding, and payer coverage

On May 15, 2026, the FDA approved atezolizumab (Tecentriq, Genentech/Roche) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech/Roche) as adjuvant treatments for adult patients with muscle-invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD), as determined by an FDA-authorized test. The agency simultaneously approved Signatera CDx (Natera) as the companion diagnostic to identify eligible patients.

This is the first FDA-approved ctDNA MRD-guided adjuvant therapy in any cancer type — a regulatory milestone that shifts treatment selection from anatomical staging alone to molecularly informed decision-making. For oncology access teams, the approval introduces a new workflow: MRD testing, companion diagnostic documentation, prior authorization for both the drug and the diagnostic, and buy-and-bill coding for IV or subcutaneous administration.

This guide is for oncology access coordinators, pharmacists, billing specialists, and payer strategists who need to understand the new indication, the companion diagnostic, coding, PA requirements, and patient support.

Short answer

The ctDNA MRD-guided paradigm

The May 15, 2026 approval is the first time the FDA has approved a therapy selected based on molecular residual disease testing rather than conventional clinicopathological staging alone. The approach enables two things simultaneously:

1. Identify patients who benefit from adjuvant therapy: Only patients with detectable ctDNA MRD after cystectomy receive Tecentriq. MRD-positive patients are at highest risk of recurrence.
2. Spare patients who may not need treatment: Patients who are ctDNA-negative after cystectomy may be able to avoid adjuvant immunotherapy, reducing exposure to immune-mediated adverse events.

MRD testing protocol

Per the FDA-approved label:

• MRD testing should be performed using Signatera CDx, a personalized, tumor-informed ctDNA assay
• Patients who are ctDNA-negative should continue serial testing (at regular intervals) until either:
  • A positive test result is obtained, OR
  • The 12-month testing window is completed
• A positive ctDNA result at any point triggers eligibility for Tecentriq initiation

Access implication: The serial testing requirement means access teams must ensure ongoing coverage for Signatera CDx (typically billed under a liquid biopsy PLA code), track testing intervals, and link each positive result to the PA submission for Tecentriq.

Clinical evidence: IMvigor011

The approval was based on the phase 3 IMvigor011 trial, which evaluated adjuvant atezolizumab versus observation in patients with MIBC after cystectomy who had detectable ctDNA MRD.

Key findings:

• In ctDNA MRD-positive patients, atezolizumab reduced the risk of disease recurrence or death (DFS) by 36% compared to placebo
• Atezolizumab reduced the risk of death (OS) by 41% in ctDNA-positive patients
• The trial used serial Signatera CDx testing to detect MRD — patients were monitored with regular blood tests within one year of cystectomy, and a positive ctDNA result triggered randomization
• ctDNA-negative patients who persistently tested negative had low risk for disease recurrence or death, supporting the "spare from treatment" paradigm
• The safety profile was consistent with the established safety profile of Tecentriq across its other indications
• Most common adverse reactions: urinary tract infection, pruritus, rash, hypothyroidism, and constipation
• Laboratory abnormalities: decreased hemoglobin and lymphocytes, increased ALT and alkaline phosphatase

IMvigor011 data were presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress and simultaneously published in the New England Journal of Medicine. A subgroup analysis was presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) in December 2025, demonstrating that the ctDNA-guided benefit was consistent across conventional pathologic staging subgroups. IMvigor011 is the first prospective Phase 3 study to demonstrate that a ctDNA-guided approach to adjuvant therapy can significantly improve survival in MIBC.

Prior authorization requirements

Step 1: Companion diagnostic authorization

Before initiating a Tecentriq PA for the MIBC indication, the patient must have a positive ctDNA MRD result from Signatera CDx. Access teams should:

1. Order Signatera CDx through Natera's ordering platform (requires tumor tissue for assay design)
2. Verify coverage for the diagnostic: Most major commercial plans and Medicare cover FDA-approved companion diagnostics. Signatera is typically billed under PLA code 0235U or similar
3. Document the positive MRD result — this is required documentation for the Tecentriq PA

Step 2: Drug PA submission

PA criteria for Tecentriq in the MIBC adjuvant indication typically require:

1. Diagnosis: Muscle-invasive bladder cancer (C67.x ICD-10 codes)
2. Surgical status: Documented radical cystectomy
3. MRD positivity: Positive ctDNA result from Signatera CDx (FDA-authorized companion diagnostic)
4. Performance status: ECOG 0–1 (or equivalent)
5. Contraindication check: No history of severe immune-mediated adverse reactions to PD-1/PD-L1 inhibitors
6. Treatment plan: Tecentriq IV or Tecentriq Hybreza SC every 3 weeks, up to 1 year

Payer-specific notes

Aetna (CPB 0909): Aetna's clinical policy bulletin for atezolizumab covers the bladder cancer indication. PA requires documented cystectomy, positive ctDNA MRD via FDA-authorized test, and ECOG status. The SC formulation (Tecentriq Hybreza) is covered under the same policy using HCPCS J9024.

Prime Therapeutics (Medical Policy): The Prime medical necessity criteria for Tecentriq include the MIBC adjuvant indication, with PA criteria aligned to the FDA label. Authorization duration is up to 12 months. Renewal requires no disease recurrence and no unacceptable toxicity.

Medicare (Part B): Tecentriq and Tecentriq Hybreza are covered under Medicare Part B as physician-administered drugs. PA is not required by traditional Medicare, but Medicare Advantage plans may impose PA. Buy-and-bill reimbursement applies.

Buy-and-bill coding

IV Tecentriq

Subcutaneous Tecentriq Hybreza

Billing note: J9024 billable units are based on 5 mg of atezolizumab. For the 1875 mg dose: 1875 ÷ 5 = 375 units per administration. Verify with each payer's specific billing guidelines.

Site-of-care considerations

Tecentriq Hybreza SC administration (~7 minutes) may enable treatment in community oncology settings, ambulatory infusion centers, or even office-based administration, compared to IV Tecentriq which requires a full infusion setup. This has site-of-care reimbursement implications:

• Office-based SC administration: typically reimbursed at higher rates than HOPD-based administration
• Payers may not differentiate reimbursement between IV and SC formulations; verify with each payer
• Genentech provides spoilage replacement for both formulations

Genentech Access Solutions

Genentech offers comprehensive patient support for Tecentriq and Tecentriq Hybreza:

Co-pay assistance

• Drug co-pay program for commercially insured patients (not valid for government-insured patients)
• Administration co-pay program to offset infusion/injection costs
• Not valid in Massachusetts, Rhode Island, or where prohibited by law
• Patients are automatically re-enrolled annually
• Three years of inactivity triggers removal from the program

Specialty pharmacy distribution

Tecentriq Hybreza Access Solutions works with specialty pharmacies to fulfill orders. Practices can use their preferred specialty pharmacy or contact Access Solutions to identify the payer-required SP.

Buy-and-bill support

Practices using buy-and-bill purchase Tecentriq/Tecentriq Hybreza directly and bill the payer. Genentech provides:

• Spoilage replacement program
• Billing and coding guides
• Reimbursement support hotline

Other Tecentriq indications

Tecentriq has 11 FDA-approved indications as of May 2026. The MIBC adjuvant indication joins:

• Adjuvant NSCLC (PD-L1 ≥1%)
• Metastatic NSCLC (PD-L1 high)
• Extensive-stage small cell lung cancer
• Hepatocellular carcinoma
• Melanoma (BRAF V600+)
• Alveolar soft part sarcoma
• Other urothelial carcinoma settings

Access teams should ensure the PA submission specifies the MIBC adjuvant indication (with ctDNA MRD documentation) to avoid confusion with Tecentriq's other approved uses.

Safety monitoring

Tecentriq carries risks of severe and fatal immune-mediated adverse reactions, including:

• Pneumonitis
• Hepatitis
• Colitis
• Endocrinopathies (hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, type 1 diabetes mellitus)
• Nephritis
• Dermatologic reactions (including SJS/TEN)
• Myocarditis

For the MIBC adjuvant setting, where patients are treated for up to 1 year after surgery, monitoring includes:

• Baseline and periodic thyroid function tests
• Liver function tests
• Renal function monitoring
• Blood glucose monitoring
• Clinical assessment for immune-mediated adverse events at each visit

What to monitor next

1. MRD testing guideline updates: NCCN is expected to update bladder cancer guidelines to incorporate ctDNA MRD-guided adjuvant therapy. Monitor NCCN Bladder Cancer Guidelines for Category of Evidence and Consensus assignments.

2. Expanded MRD-guided indications: The Tecentriq MIBC approval establishes a regulatory precedent. Other MRD-guided adjuvant therapy indications are in development (e.g., colorectal cancer, lung cancer). Access teams should monitor how this paradigm evolves.

3. SC formulation adoption: Tecentriq Hybreza SC offers a ~7-minute injection versus a 60-minute IV infusion. Payer adoption, site-of-care shifts, and patient preference data will inform formulary positioning.

4. Companion diagnostic coverage: Signatera CDx coverage varies by payer. Monitor for coverage policies specific to the bladder cancer MRD indication.

5. Manufacturing and supply: Tecentriq Hybreza is a single-dose vial product. Monitor for any distribution limitations or supply constraints.

Sources

• FDA. FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease (May 15, 2026). fda.gov/drugs/resources-information-approved-drugs
• Genentech. FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment (May 15, 2026). gene.com/media/press-releases
• Genentech. TECENTRIQ HYBREZA Prescribing Information (2026). tecentriq-hcp.com/hybreza.html
• Genentech. TECENTRIQ Billing and Coding Guide. genentech-access.com
• Genentech Pro. Tecentriq Hybreza Product and Access Information. genentech-pro.com
• Prime Therapeutics. Tecentriq Hybreza Medical Necessity Criteria (2025). modahealth.com
• Aetna. Atezolizumab Clinical Policy Bulletin 0909 (2026). aetna.com/cpb/medical/data/900_999/0909.html
• OncLive. FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC (May 15, 2026). onclive.com
• Targeted Oncology. FDA Approves Adjuvant Atezolizumab for ctDNA MRD-Positive MIBC (May 2026). targetedonc.com